menu search

MNOV / MediciNova Posts Promising Data From COVID-19 Treatment Candidate

MediciNova Posts Promising Data From COVID-19 Treatment Candidate
MediciNova Inc (NASDAQ: MNOV) says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo for all four clinical endpoints analyzed.  The trial achieved statistical significance for one of the co-. Read More
Posted: Jun 8 2022, 09:15
Author Name: Benzinga
Views: 1025100

MNOV News  

Medicinova stock up on European patent award

By Proactive Investors
August 16, 2023

Medicinova stock up on European patent award

Medicinova Inc (NASDAQ:MNOV) stock started Wednesday on the front foot boosted by a patent award in Europe. The European Patent Office has given prote more_horizontal

MediciNova Posts Promising Data From COVID-19 Treatment Candidate

By Benzinga
June 8, 2022

MediciNova Posts Promising Data From COVID-19 Treatment Candidate

MediciNova Inc (NASDAQ: MNOV) says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements  more_horizontal


Search within

Pages Search Results: